nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-996AC750·Framework v5.0·Pipeline v0.4·Evaluated 15 Jun 2026·OECD: 3.2 Clinical medicine·Subfield: Genetics·Basis: Full text·Type: Randomized controlled trial

Effects of Mediterranean Diet, Curcumin, and Resveratrol on Mild-to-Moderate Active Ulcerative Colitis: A Multicenter Randomized Clinical Trial.

Erol Doğan et al.Erol Doğan, Karaca Çelik, Baş et al.·2024·Nutrients·10.3390/nu16101504 ↗

In brief

A competent multicentre diet-plus-supplement RCT showing curcumin and resveratrol add no benefit over a Mediterranean diet, undermined by the absence of any non-diet control arm.

ReliabilityCaveats3 of 4 checks completeRead the 2 entries ↓
Abstract

This study aimed to investigate the effects of the Mediterranean diet (MD), combined with curcumin and resveratrol supplementation, on disease activity, serum inflammatory markers, and quality of life in patients with mild-to-moderate active ulcerative colitis (UC). This study was designed as a prospective multicenter three-arm randomized controlled trial. Participants were randomized to the MD, MD + curcumin, and MD + resveratrol groups. All participants were placed on the MD for 8 weeks. The MD + curcumin group also received 1600 mg/day of curcumin supplementation, whereas the MD + resveratrol group received 500 mg/day of resveratrol supplementation for 8 weeks. Anthropometric measurements, Truelove-Witts Index, Short Form-36, Inflammatory Bowel Disease Questionnaire, Mediterranean Diet Adherence Scale (MEDAS), and laboratory tests were performed at baseline and postintervention. Within-group comparisons showed that MD, MD + curcumin, and MD + resveratrol interventions were effective in reducing disease activity and inflammation and improving quality of life in individuals with UC (p < 0.05). Between-group comparisons revealed no significant difference in all parameters except for the pain subparameter of SF-36 and the MEDAS score (p < 0.05). The MD is an effective and safe intervention to be used in clinical practice in individuals with UC.

Strengths · Limitations

Strengths

#contribution

Honest null finding on supplement add-on

By standardizing the Mediterranean diet across all three arms, the trial isolates the add-on question and reports that curcumin and resveratrol produced no broad between-group superiority. This narrows an interpretive ambiguity in prior supplement studies that lacked dietary control.

↳ Results Tables 4–7; Discussion

#methodological rigour

Validated instruments and standardized measurement

The study uses disease-specific, validated outcome tools (Truelove-Witts Index, SF-36, IBDQ, MEDAS) and standardized anthropometry under ISAK guidelines performed by a single researcher. This strengthens measurement consistency across the two sites.

↳ Methods 2.4.2–2.4.9

#reporting

Clear, well-organized reporting

The manuscript follows a conventional, readable structure and presents its core result pattern transparently across tables, making the comparative findings easy to follow.

↳ Results §3; Tables 4–7

Limitations

#methodological rigour

No non-diet control arm

All participants received the Mediterranean diet, so within-group improvements cannot be attributed to the intervention rather than natural disease course, regression to the mean, or concurrent medical treatment. This directly undercuts the conclusion that the diet is effective.

↳ Methods 2.2; Discussion

#reporting

Conclusions overreach the design

The abstract and conclusions assert the Mediterranean diet is an effective and safe clinical-practice intervention, a causal and safety claim that an unblinded, controlled-only-against-supplements trial without systematic harms monitoring cannot support.

↳ Abstract; Conclusions §5

#methodological rigour

Unblinded design with multiplicity risk

Subjective primary outcomes are assessed without blinding, raising performance and detection bias, and many within-group significance tests are reported without a pre-specified primary endpoint or global multiplicity correction. Together these weaken confidence in the positive within-group claims.

↳ Methods 2.2, 2.5; Results Tables 3–7

Does this match your read? Add your assessment ↓

Nabu Commentary

The evaluation converged on a clinically relevant but methodologically mid-tier RCT whose most defensible result is that adding curcumin or resveratrol to a Mediterranean diet conferred no broad short-term benefit over the diet alone. The decisive constraint is the comparator structure: with every arm on the Mediterranean diet and no usual-care or placebo control, within-group improvements cannot be causally attributed to the diet, which makes the abstract and conclusion language about clinical-practice efficacy and safety an overreach. Methodological Rigour was the most contested dimension, with assessments differing over how much credit the randomized multicentre design and a priori power calculation should earn against the absence of blinding, allocation-concealment reporting, a pre-specified primary endpoint, and systematic harms monitoring; the settled score reflects competent but materially under-executed methodology. Impact potential rests on a genuine clinical need and identifiable stakeholders, but the small, single-country, 8-week sample and missing endoscopic or calprotectin endpoints keep the findings preliminary and contingent on replication.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.1±0.2

Contribution
3.2

The score reflects a genuine but modest advance: the first standardized-diet comparison isolating whether curcumin or resveratrol add benefit on top of a Mediterranean diet, with an honestly reported null between-group result. It is constrained because the design cannot support the headline claim that the Mediterranean diet itself is effective in UC.

Introduction final paragraph; Results Tables 4–7; Discussion

this study is the first to examine the impact of curcumin and resveratrol supplements using a standardized and effective dietary model

Methodological Rigour
2.7

Randomized multicentre recruitment, an a priori power calculation, and validated instruments are present, but allocation concealment and blinding are not described, no primary endpoint is pre-specified, ITT/missing-data handling is absent, and harms are not systematically reported. These execution gaps place Methodological Rigour in the band where methodological choices introduce meaningful uncertainty.

Methods 2.1–2.5; Conclusions §5

Truelove–Witts Index-based block randomization with a 1:1:1 allocation ratio

Reporting
3.5

The manuscript is well-structured and the core result pattern (broad within-group improvement, limited between-group differences) is communicated clearly. The recurring precision problem is causal language in the abstract and conclusions that exceeds what the comparator structure establishes.

Abstract; Results §3; Conclusions §5

The MD is an effective and safe intervention to be used in clinical practice in individuals with UC.

Positioning
3.4

The paper engages prior MD, curcumin, and resveratrol literature and the ESPEN guideline gap appropriately. It is held back because the limitations section omits the most consequential constraint, the absence of a non-MD control, and does not address natural disease fluctuation or regression to the mean.

Introduction; Discussion limitations paragraph

there is insufficient evidence for specific dietary approaches in individuals with active disease

Reliability

Caveats3 of 4 checks


Internal CoherenceNoted

Reported counts are internally consistent across abstract, methods, and results (48 enrolled, 46 analyzed), but the Abstract and Conclusions frame the Mediterranean diet as 'effective and safe' for clinical practice beyond what a design with no non-MD control can support, and numerous within-group significance tests are reported without a pre-specified primary endpoint or global multiplicity strategy.

Research ConductNoted

Ethics approval (KN: 2021/24-30122021), trial registration (NCT05761327), and informed consent are declared in Methods 2.1, which is positive, but registration timing relative to enrolment is not clarified in-text, no conflict-of-interest disclosure is visible despite a named supplement manufacturer, and no data or code availability statement is present.

Flags: 2 declared / 5 total

Reference IntegrityPending

Not yet checked.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Oral and gastrointestinal · Inflammatory bowel disease
Type of advanceEmpirical
Route to useNamed
AdvanceExtends
BeneficiariesSmall
CitationsFWCI 17.1
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessPiloted
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

A small 46-participant multicenter randomized trial showed within-group improvements, but no independent confirmatory trial or external validation of the primary claim exists yet.

From the paper
“The MD is an effective and safe intervention to be used in clinical practice in individuals with UC.”

The conclusion explicitly names clinical practice as the setting where clinicians would apply the Mediterranean diet for ulcerative colitis patients.

Pathway

Gastroenterologists and dietitians in IBD clinics would prescribe Mediterranean diet counseling as an adjunct to standard medical therapy for mild-to-moderate ulcerative colitis.

Barrier

The small sample, short 8-week duration, lack of endoscopic and calprotectin endpoints, and absence of between-group supplement effects limit confidence for routine clinical adoption.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. The regulatory role of Nrf2 in antioxidants phase2 enzymes and IL-17A expression in patients with ulcerative colitis

    Milad Sabzevary-Ghahfarokhi, Mojtaba Shohan, Hedayatollah Shirzad, et al. · 2018 · Basic medicine

    Primary claim

    Oxidative stress in inflamed colonic tissue can induce Nrf2 gene expression. The performance of Nrf2 transcription factor may lead to the induction of GST-A4 and PRDX1.

    Unsupported
    Evidence Score
    2.3±0.1
    Reliability
    Caveats
  2. Curcumin for maintenance of remission in ulcerative colitis

    Kumar, Ahuja, Sankar, et al. · 2012 · Clinical medicine

    Evidence Score
    3.8±0.1
    Reliability
    Caveats
  3. The Use of Curcumin as a Complementary Therapy in Ulcerative Colitis: A Systematic Review of Randomized Controlled Clinical Trials

    Coelho, Romi, Ferreira, et al. · 2020 · Clinical medicine

    Evidence Score
    3.1±0.1
    Reliability
    Caveats

How the rubric works →